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a. . Problems wouldn’t be called hurdles if there were
not a way to overcome them. (1)
arly identification of asymptomatic subjects
who are at a high risk of developing an
acute coronary syndrome (ACS) remains
the biggest challenge for the non-invasive
mager. Prospective recognition of rupture-prone
therosclerotic plaques in key vascular beds, such
s the coronary and carotid arteries, is likely to
nable strategies to limit acute coronary events
nd strokes (2). Traditionally, anatomic or struc-
ural imaging has been used to detect subclinical
igh-risk plaques (HRP) and distinct morpho-
ogic features have been shown to be associated
ith plaque disruption. Acute coronary events are
ften associated with plaques that may not neces-
arily be flow limiting and morphologically demon-
trate large volumes with significant positive remod-
ling and bulky necrotic cores (2). These plaques are
lmost always covered by attenuated and inflamed
brous caps. Whereas the morphological character-
stics of HRP have been defined by imaging strate-
ies such as computed tomography (CT) angiogra-
hy and magnetic resonance imaging, molecular
maging offers the best option for demonstration of
laque inflammation.
Of the numerous targeting strategies used for
maging inflammation, 18F-fluorodeoxyglucose
FDG)–positron emission tomography (PET) im-
ging has been most commonly investigated for
ocalization of vascular inflammation (3). FDG
ptake occurs preferentially in the metabolically
ctive cells and has been used as a reliable investi-t
rom the *Division of Cardiology, University of California-Irvine, Irvine,
alifornia, and the †University of Minnesota, Minneapolis, Minnesota.ative tool in differentiating malignant lesions
rom benign masses and in localizing chronic in-
ammatory processes. Since neutrophils are rather
elf-sufficient in their energy production, early in-
ammatory lesions do not accumulate FDG until
here is a critical mass of macrophage-rich infiltrates.
theromatous plaques, similar to other chronic inflam-
atory foci, concentrate FDG because macrophages
ack efficient glucose generating machinery and re-
uire external sources of glucose supply to conduct
heir scavenging function. Incidental FDG uptake
as been reported, commonly in aorta and large ar-
eries and more rarely in the coronary vasculature
4), in patients being investigated for various malig-
ancies. Such FDG uptake was hypothesized to
epresent an inflammatory state in atheroscle-
otic lesions (5) and was subsequently traced to
istologically-verified macrophage infiltration in
arotid endarterectomy specimens (6). In prospec-
ive investigations, FDG uptake occurred selec-
ively in symptomatic carotid vascular disease (7)
nd was substantially reduced after statin therapy
8). Although imaging atheroma in large vessels
eemed useful, demonstration of inflammation
n coronary vessels, an area with possibly the
reatest prognostic value, has remained elusive.
f successful, such imaging would even make it
ossible to monitor efficacy of some interven-
ions.
Multiple practical hurdles in the clinical feasi-
ility of such imaging have so far limited what we
ould do in this arena. Cardiomyocytes are meta-
olically active cells and consume variable quanti-
ies of glucose that is difficult to suppress com-
letely, therefore, differentiation of coronary
ptake from the background of myocardial uptake
nd blood pool activity is not always easy. Fur-
hermore, the lesions are expected to be not too
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449ig (nearing the limits of spatial resolution of cur-
ent imaging techniques) and FDG concentration
eeds to be intense enough, with high target-to-
ackground ratio, to be detectable noninvasively.
he study by Rogers et al. (9) presented in this
ssue of iJACC has tackled many of these prob-
ems and, more importantly, demonstrated the
otential utility of molecular imaging in the coro-
ary bed. They show that it is possible to pro-
pectively image coronary inflammation and that
atients with unstable coronary syndromes harbor
reater inflammation than those with stable syn-
romes. This prospectively extends to the coro-
ary beds, data that was known from other, larger
ascular beds.
One major problem that needs to be addressed
efore obtaining clear evidence of coronary in-
ammation is suppressing background (mainly
yocardial) FDG uptake. Although fatty acids
re the staple substrate for the myocardium under
ormal aerobic conditions, cardiomyocytes can
onsume almost any kind of alternative fuel, in-
luding glucose, lactate, pyruvate, and even ke-
ones (10). As expected, glucose serves as the pre-
erred substrate for oxidative metabolism in the
ed state, and fatty acids in fasting states. It was,
herefore, logically presumed that fasting would
ubstantially suppress myocardial FDG uptake.
lthough fasting up to 18 h increases fatty acid
ptake and metabolism in the myocardium
11,12), it does not completely suppress glucose
ptake. It therefore becomes necessary to manipu-
ate the myocardial menu to obtain a cleaner
ackground.
Fatty acid oxidation can be augmented, with a
orresponding decrease in glucose metabolism, us-
ng a high-fat, low-carbohydrate meal a day be-
ore, supplemented by an oil drink just before the
can (13,14). Some glucose consumption contin-
es even in the presence of fatty acid excess, and
s also affected by comorbidities, drugs, and hor-
onal milieu (15). For instance, hypertension and
igh adrenergic states promote, and beta-blockers
16) should restrict, glucose over free fatty acid
se. Modulating intracellular calcium kinetics us-
ng calcium-channel blockers can inhibit glucose
ransport; their effect on heart rate is likely to fur-
her help in coronary artery hybrid FDG inflam-
ation and CT angiographic studies (17). Tykrzykowska et al. (14) showed that adequate
ubstrate manipulation can suppress myocardial
ptake to an extent that is sufficient to improve
oronary inflammation imaging. In two-thirds
f the patients in the retrospective study, myocar-
ial suppression was good or adequate; inadequate
uppression was attributed to self-reported dietary
onadherence. FDG uptake was clearly visualized
n up to one-half of the patients in 1 or more
oronary segments. Rogers et al. (9) successfully
se a similar dietary regimen to prospectively as-
ess the feasibility of myocardial suppression of
DG uptake.
There remain many unanswered critical issues in
anipulating myocardial substrate utilization as a
ethod to improve signal-to-noise ratio. One ques-
ion that has been raised is whether diet or pharma-
ologic intervention would also affect FDG uptake
n coronary plaque macrophages and thus obscure
he true picture (15). Using examples of tumor
DG uptake (18) and that from nonvascular in-
ammatory sites (13), Fox and Strauss (15) con-
luded that this may not be a major issue. It is
elieved that the hypoxic plaque microenviron-
ent should promote a glycolytic state even in
he presence of an altered nutrient environment,
nd thus not affect plaque FDG concentration
hile favorably suppressing the myocardial up-
ake. A second issue with PET for identifying
oronary inflammation is the small size of the re-
ion of interest and the target localization in a
oving heart. The spatial resolution limits of
ET imaging are 4 to 6 mm at the center of
he field of view and 0.125 ml volume resolution
15). In a CT angiographic study, we have re-
ently reported plaque volume of 135  14 mm3
95% confidence interval, 107–163 mm3) and the
ecrotic core or low attenuation plaque volume of
0  3 mm3 (14–27mm3) of the culprit lesions
19). The current study reassures that target le-
ions are well within the realm of imaging. Better
ethods for correcting attenuation, coronary mo-
ion (respiratory and cardiac), and partial-volume
ffects should further improve our ability to iden-
ify coronary inflammation more precisely (15).
Rogers et al. (9) have presented an excellent
tudy design wherein the coronary stents were
sed as landmarks to identify site of tracer uptake.
he FDG uptake colocalized with the stents in
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450atients with ACS, but stented coronary segments
n patients with chronic stable disease did not
oncentrate FDG. Radiotracer uptake in the
tented lesions correlated with other well-recog-
ized markers of inflammation, such as high-sen-
itivity C-reactive protein levels. The authors have
legantly incorporated multiple manipulations and
xploited metabolism to allow better imaging of
oronary vessels, an area that has continued to
efy molecular imaging. However, it is obvious
hat much remains to be done and proven beforefluorodeoxyglucose positron emis- Roentgenol 2008;1trong outcome-based reason to pursue such imag-
ng. Nevertheless this exciting area has opened up
ntriguing possibilities. Although not yet close, we
re fairly close.
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